Abiraterone in metastatic salivary duct carcinoma.
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy with limited evidence guiding standard treatment. SDC is known to overexpress the androgen receptor, with only a handful of cases reporting responses to androgen blockade. This report presents a case of SDC responding to multiple lines of androgen blockade, including a rapid response to abiraterone, a CYP17 inhibitor effective in prostate cancer. This case represents the first published report of SDC responding to abiraterone and illustrates that androgen receptor expressing SDC may be treated with multiple lines of androgen blockade, including newer agents such as abiraterone. This case suggests that SDC may continue to be androgen-dependent after progression on androgen deprivation, which is analogous to prostate cancer.
From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Damien
D
Urban
From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Danny
D
Rischin
From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Christopher
C
Angel
From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Ieta
I
D'Costa
From the Departments of Medical Oncology, Pathology, and Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Benjamin
B
Solomon
D000736:Androstenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D018987:Salivary Ducts / Q000473:pathology*; D012468:Salivary Gland Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000736:Androstenes; D000970:Antineoplastic Agents; C089740:abiraterone